



Cumulative Index

Volume 23

March	LUNG CANCER, pages 1–282
June	TROPICAL LUNG DISEASE, pages 283–528
September	LUNG DISEASE DUE TO NONTUBERCULOUS MYCOBACTERIAL INFECTIONS, pages 529–694
December	OCCUPATIONAL AND ENVIRONMENTAL LUNG DISEASE, pages 695

Note: Page numbers of article titles are in **boldface** type.

A

- Accelerated silicosis, 829
- Acid-fast microscopy, in diagnosis of nontuberculous mycobacteria, 587
- Acquired immunodeficiency virus (AIDS), in the tropics, pulmonary manifestations of, 298, **355–367**
- bacterial pneumonias, 357–360
 - fungal respiratory infections, 360–362
 - idiopathic pulmonary processes, 364
 - immunologic aspects of, 298–299
 - neoplastic pulmonary diseases, 363–364
 - non-tuberculous mycobacterial diseases, 360
 - opportunistic lung infections in, 298–299
 - parasitic infections, 299–304, 362
 - tuberculosis, 355–357
 - viral respiratory infections, 362–363
- See also *Human immunodeficiency virus (HIV)*.
- Acute inhalation injury. See *Inhalation injury, acute*.
- Acute lung injury, in malaria, 461–462, 463–465
- Acute phase proteins, innate immune defense by, 288–289
- Acute pneumonitis. See *Pneumonitis, acute*.
- Adeno-associated virus, in lung cancer, 266
- Adenocarcinoma, and lung cancer, 68–71
- Adenomatous hyperplasia, atypical, and lung cancer, 265–266
- Adjunctive therapy, for pulmonary disease caused by *Mycobacterium avium* complex, 637
- Adult respiratory distress syndrome (ARDS), in the tropics, **445–455**
- etiology and recognition, 445–446
 - heat stroke as cause of, 451
 - leptospirosis as cause of, 451, 474
 - malaria as cause of, 446–449, 461–462, 463–465
 - management and outcome, 452
 - organophosphate poisoning as cause of, 451
 - paraquat poisoning as cause of, 451
 - pulmonary tuberculosis as cause of, 449–450
 - scorpion bite as cause of, 451
 - strongyloidiasis as cause of, 450–451
 - typhoid as cause of, 450
- Aerosols, as habitat for environmental opportunistic mycobacteria, 534–535
- Age, as factor in lung cancer, 4–5
- in functional evaluation before lung resection, 161
- Agricultural lung disease, **801–817**
- asthma, 807–809
 - asthma-like syndrome, 809–810
 - bronchitis, 810
 - clinical evaluation for, 803
 - hypersensitivity pneumonitis, 803–806
 - organic toxic dust syndrome, 806–807
 - sources of exposure, 802–803
 - mites, 803
 - organic dusts, 802
 - toxic gases, 802–803
 - toxic gas inhalation and acute respiratory failure, 810–812
 - workforce, 802

- Agricultural workers, occupational lung disease in, **801-817**
clinical evaluation of, 803
description of workforce, 802
- AIDS. See *Acquired immunodeficiency virus*.
- Air pollution, outdoor, health effects of, **763-782**
experimental and toxicologic findings, diesel exhaust, 770
ozone and other gaseous pollutants, 770-771
particulate matter, 768-770
observational findings, effects of pollutant sources, 767-768
ozone and other gaseous pollutants, 767-768
particulate matter, 765-768
research needs, 771
- Airway stents, in lung cancer, 247-250
- Airways, inflammation of, noninvasive methods of characterizing in work-related asthma, 743-745
exhaled nitric oxide, 743-744
induced sputum analysis, 744-745
occupational diseases of, from chronic low-level exposure to irritants, **727-735**
upper, occupational disease of. See *Upper airway disease, occupational*.
- Alcoholism, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Allergic bronchopulmonary aspergillosis, eosinophilic disease in, 381-383
Mycobacterium avium complex pulmonary disease associated with pre-existing, 645
- Allergic granulomatosis and angiitis. See *Churg-Strauss syndrome*.
- Allergic rhinitis, occupational, 719-720
- Aluminum industry exposures, studies of work-related asthma and, 742
- Alveolar echinococcosis, of the lungs, 402-405
- Alveolitis, extrinsic allergic, granulomatous lung disease due to, in the tropics, 337
- Amebiasis, in the tropics, eosinophilic disease due to pleuropulmonary, 386
immunologic aspects, 303-304
radiologic imaging of, 321-322
thoracic, **479-492**
and HIV/AIDS, 487-488
bacterial superinfections with, 486
clinical features, 482-483
diagnosis, 483-486
differential diagnosis, 486
geographic distribution, 479
infection by free-living amoebae, 488-489
modes of pulmonary involvement, 481-482
pericardial, 487
sociodemographic distribution, 479
treatment, 486-487
- Amikacin, for pulmonary disease caused by *Mycobacterium avium* complex, 635
National Jewish Medical and Research Center policy and procedures for, 638-640
- Ammonia, anhydrous, acute inhalation injury due to, 711
inhalation of, and acute respiratory failure in agriculture workers, 811-812
- Amyloidosis, lung involvement in, in familial Mediterranean fever, 507-508
versus Whipple's disease, 515
- Aneurysms, in Behçet's disease, aortic arch, 499
pulmonary artery, 494-498
- Angiogenesis, and lung cancer, 94
- Anhydrous ammonia, acute inhalation injury due to, 711
inhalation of, and acute respiratory failure in agriculture workers, 811-812
- Animals, as habitat for environmental opportunistic mycobacteria, 535-536
- Anthrax, inhalational, bioterrorism-related, 786-790
- Anti-Hu antibody syndrome, 260-261
- Antibiotic resistance, in environmental opportunistic mycobacteria, 539-540
- Antibody responses, to parasites, 291
- Antigen mimicry, by parasites, for evasion of host defense mechanisms, 295
- Antigen shift, by parasites, for evasion of host defense mechanisms, 295
- Antimicrobial treatment, of nontuberculous mycobacterial lung disease, for *Mycobacterium avium* complex, **633-641**
in cystic fibrosis patients, 659-660
with rapidly growing mycobacteria, 628-630
- Antiretroviral therapy, highly active (HAART), for HIV, combined with therapy for tuberculosis, 357, 358

- interactions with drugs used to treat *Mycobacterium avium* complex in HIV-infected patients, 669
- Aortic arch, aneurysm of, in Behçet's disease, 499
- Apnea, obstructive sleep, assessment of pulmonary impairment and disability, 857
- Apoptosis, and lung cancer, 94
- Arterial blood gas measurements, in functional evaluation before lung resection, 161
- Arthritis, *versus* Whipple's disease, 515
- Ascariasis, immunologic aspects of, 302-303
- Aspergillosis, allergic bronchopulmonary, eosinophilic disease in, 381-383
Mycobacterium avium complex pulmonary disease associated with pre-existing, 645
- Asphyxiants, chemical, as chemical weapons, 797-798
- Aspiration, chronic, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Assessment, of occupational and environmental exposures that cause lung disease, **695-705**
- Asthma, assessment of pulmonary impairment and disability in, 854-855
environmental tobacco smoke and adult, **749-761**
causal association of, 759-760
exacerbation of pre-existing adult asthma, 755-759
new-onset adult asthma and, 749-752
new-onset wheezing and, 753-754
prevalence of exposure, 749
from chronic low-level exposures to irritants, **727-735**
epidemiology of, 729-730
etiology of, 731
management and prevention of, 732-733
population-attributable risk of, 731-732
in agriculture workers, 807-809
clinical presentation and evaluation, 809
epidemiology, 807-808
etiologic agents and pathogenesis, 808-809
treatment, 809
protection from, in familial Mediterranean fever, 506-507
work-related, **737-747**
definition, 737, 739
diagnosis, 737-739
incidence and prevalence, 739-741
longitudinal inception cohort and apprentice studies, 742-743
aluminum industry exposures, 742
laboratory animal, flour, and latex exposures, 742-743
machining fluid exposures, 742
noninvasive methods of characterizing airway inflammation, 743-745
exhaled nitric oxide, 743-744
induced sputum analysis, 744-745
- Asthma-like syndrome, in agriculture workers, 809-810
- Atopic disorders, and tropical infections, 305
- Atypical adenomatous hyperplasia, and lung cancer, 67
- Autonomic dysfunction, due to nerve gas, 793-794
- Azithromycin, for pulmonary disease caused by *Mycobacterium avium* complex, 634-635, 636
in HIV-infected patients, 668
in patients with pre-existing lung disease, 648
Lady Windermere syndrome, 680
- ## B
- B lymphocytes, role in immune system, 290-291
- Bacillus anthrax*, as biological weapon, inhalational anthrax due to, 786-790
- Bacillus Calmette-Guerin* (BCG) vaccination, for prevention of tuberculosis, 346-347
- Bacterial diseases, in the tropics, granulomatous lung diseases caused by, 334-335
brucellosis, 334-335
tularemia, 335
pneumonias, as pulmonary manifestation of HIV/AIDS, 357-360
melioidosis, 359-360
nocardiosis, 359
pneumococcal, 357-359
Pneumocystis carinii, 359
Rhodococcus equi infection, 360
- Behçet's disease, pulmonary complications of, **493-503**
aortic arch involvement, 499
diagnosis, 493-494
epidemiology, 494
intracardiac thrombus formation, 499
laboratory findings, 494
pathogenesis, 494
pathology, 494

- pleural and pulmonary parenchymal findings, 498
 - prognosis, 500
 - pulmonary artery aneurysm, 494-498
 - superior vena cava occlusion, 498-499
 - treatment, 499-500
- Berylliosis, granulomatous lung disease due to, in the tropics, 337-338
- Beryllium disease, chronic, **835-847**
- beryllium sensitization and, 835-836
 - exposure risks associated with, 837-839
 - immunopathogenesis of, 836-837
 - interaction between gene and environmental factors, 844
 - role of genetics in pathogenesis of, 837-844
- Beryllium sensitization, chronic beryllium disease and, 835-836
- Bilharziasis. *See Schistosomiasis.*
- Biofilms, as habitat for environmental opportunistic mycobacteria, 534
- Biological hazards, assessing exposure to, 699-701
- home assessment checklist for, 700
- Biological weapons, pulmonary manifestations of intentionally released agents, **783-800**
- biological threat classification, 784
 - overview, 783-784
 - pulmonary syndromes associated with, 784-790
 - acute pneumonitis, 784-786
 - hemorrhagic mediastinitis, 786-790
- Birds, as habitat for environmental opportunistic mycobacteria, 535-536
- Bithionol, for paragonimiasis, 416, 427
- Blastoma, pulmonary, 76
- Blastomycosis, granulomas in, 333-334
- Blister agents, as chemical weapons, 791, 794-796
- classification of, 791
 - irritation and inflammation of lungs and airways, 794-796
- Blood agents. *See Chemical asphyxiants.*
- Brachytherapy, in lung cancer, 246-247
- Bronchial hygiene, for *Mycobacterium avium* complex pulmonary disease, 637
- in patients with pre-existing lung disease, 651
- Bronchial-associated lymphoid tissue (BALT), role in disease resistance, 285
- Bronchiectasis, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Bronchiolitis obstructive obliterans pneumonitis, eosinophilia in, 390
- Bronchitis, due to mineral dust exposure. *See also Coal mine and silica dust, respiratory disease from, definition of, 819*
- epidemiology of, 823
 - in agriculture workers, 810
- Bronchocentric granulomatosis, eosinophilic disease in, 383-384
- in the tropics, 337
- Bronchogenic cancer, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Bronchogenic carcinoma, paraneoplastic syndromes associated with, **257-264**
- anti-Hu antibody syndrome, 260-261
 - cancer-associate retinopathy, 261
 - ectopic Cushing's syndrome, 258
 - encephalomyelitis, 260-261
 - humoral hypercalcemia of malignancy, 259
 - Lambert-Eaton myasthenic syndrome, 261-262
 - neurologic, 259-262
 - SIADH, 258-259
- Bronchoscopy, flexible. *See Flexible Bronchoscopy.*
- in lung cancer, **241-256**
 - airway stents in, 247-250
 - brachytherapy in, 246-247
 - for curative intent, 253
 - photodynamic therapy in, 250-253
 - tracheobronchial tumors, 241-242
- Brucellosis, chronic, eosinophilic disease in, 384
- in the tropics, granulomatous lung diseases caused by, 334-335
- Bupropion, in lung cancer prevention, 33
- ## C
- Cadmium, acute inhalation injury due to, 711
- Cancer, bronchogenic, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- lung. *See also Lung cancer and Malignancies., in the tropics, as pulmonary manifestation of HIV/AIDS, 364*
 - immunologic aspects of, 304-305

- Carboplatin, in small-cell lung cancer, 231
- Carcinogens, occupational, as factor in lung cancer, 15-16
- Carcinoma in situ, and lung cancer, 65-67
- Carcinomasarcoma, of lung, 76
- Cardiopulmonary exercise testing, in functional evaluation before lung resection, 164-167
- Cardiopulmonary exercise tests, for evaluation of pulmonary impairment and disability, 852-853
- Cathelicidins, role in immune system, 288
- Cavitary disease, pulmonary, due to *Mycobacterium avium-intracellulare* complex, radiology of, 606-607
- Centers for Disease Control (CDC), algorithm for treatment of bioterrorism-related inhalational anthrax, 789
- classification of biological weapons, 784
- Cestodes. See *Echinococcosis and Hydatid lung disease*.
- Chagas' disease, pulmonary, immunologic aspects of, 304
- Chemical hazards, assessment of exposure to, 698-699
- Chemical manufacturers, requesting trade secret information from, 704
- Chemical weapons, pulmonary manifestations of, **790-798**
- classification of chemical threat agents, 790-791
 - hazardous materials principles, 791-792
 - overview, 790
 - pulmonary syndromes associated with, 792-798
 - autonomic dysfunction, 793-794
 - chemical asphyxiants (blood agents), 797-798
 - irritation and inflammation of lungs and airways, 794-797
- Chemokines, role in immune system, 289
- Chemoprevention, of early lung cancer, 43-45
- Chemotherapy, in small-cell lung cancer, 15-16
- 4-epidoxorubicin, 231
 - alternating chemotherapy, 230-231
 - alternation of doses of, 231-232
 - carboplatin, 231
 - cyclophosphamide, 231
 - duration of administration of, 232
 - etoposide, 231
 - ifosfamide, 231
 - in poor performance status patients, 232
 - weekly administration of, 231
 - with radiation therapy, for non-small cell lung cancer, 199-201
 - in stage IIIA unresectable NSCLC, 211-212
 - in stage IIIB NSCLC, 211-212
- Chest radiographs, for evaluation of pulmonary impairment and disability, 853-854
- Children, tuberculosis in, in tropical countries in, diagnosis of, 345
- epidemiology of, 341-342
- Chlorine, acute inhalation injury due to, 711
- as a chemical weapon, irritation and inflammation of lungs and airways due to, 796-797
- Choke agents, as chemical weapons, irritation and inflammation of lungs and airways due to, 796-797
- Chronic beryllium disease. See *Beryllium disease, chronic*.
- Chronic low-level exposures to irritants, occupational airways diseases from, **727-735**
- Chronic obstructive pulmonary disease (COPD), assessment of pulmonary impairment and disability in, 855
- caused by coal mine and silica dust, 823-824
- due to chronic low-level exposures to irritants, **727-735**
- clinical spectrum of, 727-728
 - epidemiology of, 728-729
 - etiology of, 730-731
 - management and prevention of, 732-733
 - population attributable risk, 731-732
 - Mycobacterium avium* complex pulmonary disease associated with pre-existing, 644-645, 647
- Churg-Strauss syndrome, eosinophilia in, 390-391
- Cigar smoking, lung cancer caused by, 10
- Cigarette smoking, cessation of. See *Smoking cessation*.
- lung cancer caused by, 5-10, 27-28
- Ciprofloxacin, for pulmonary disease caused by *Mycobacterium avium* complex, 635
- Clarithromycin, for pulmonary disease caused by nontuberculous mycobacteria, *Mycobacterium avium* complex, 634-635, 636
- in HIV-infected patients, 668

- in Lady Windemere syndrome, 680
- in patients with pre-existing lung disease, 648-651
- rapidly growing mycobacteria, 628-630
- Clinical presentation, of nontuberculous mycobacterial pulmonary disease, 599-600
 - due to *M. avium* complex, with pre-existing lung disease, 645-647
 - due to *M. kansasii*, 614-615
 - due to rapidly growing mycobacteria, 626-628
 - in HIV-infected patients, 666-668
 - Lady Windemere syndrome, 675-676
- Clofazamine, 669
 - for pulmonary disease caused by *Mycobacterium avium* complex, 635
- Clonidine, in lung cancer prevention, 33
- Coal mine and silica dust, respiratory disease from, **819-834**
 - clinical evaluation for, 824-828
 - chest imaging, 826-828
 - history, 824
 - occupational history, 824-826
 - other exposure history, 826
 - pathology, 828
 - physical examination, 826
 - physiologic testing, 828
 - smoking history, 826
 - definitions, 819-820
 - epidemiology of, 822-824
 - chronic obstructive lung disease caused by, 823
 - mortality data, 822
 - prevalence of radiologic pneumoconiosis, 822-823
 - exposed populations, 820-821
 - coal mine dust, 820-821
 - silica dust, 821
 - special syndromes of silica dust-induced lung disease, 828-830
 - treatment, 830-831
 - compensation, 830
 - medical legal opinion, 831
 - removal from exposure, 830
 - supportive care, 830
- Coal workers' pneumoconiosis. See also *Coal mine and silica dust, respiratory disease from*, definition of, 819
- Colonization, with nontuberculous mycobacteria, differentiating from infection and disease, **599-601**
- Compensation, for disability due to occupational disease, for coal mine and silica dust-induced lung disease, 830
- Complement system, role in immune system, 289
- Computed tomography (CT), for diagnosis of coal workers' pneumoconiosis and silicosis, 828
 - for evaluation of pulmonary impairment and disability, 854
 - in lung cancer screening, **49-57**
 - effectiveness of, assessment of, 50
 - ELCAP study, 50-55
 - future efforts in, 56
 - study results, 56
 - in pulmonary *Mycobacterium avium*-intracellular complex disease, 607
 - in solitary pulmonary lesion diagnosis, 124-127
 - in solitary pulmonary nodule staging, 128-133
 - spiral, in lung cancer screening, 42-43
- Conducting airway injury, acute inhalational, 709
- COPD. See *Chronic obstructive pulmonary disease*.
- Cryptococcosis, as pulmonary manifestation of HIV/AIDS in tropics, 360-361
 - granulomas in, 333
- CT. See *Computed tomography*.
- Culture, mycobacterial, in diagnosis of nontuberculous mycobacteria, 588-589
- Cushing's syndrome, ectopic, 258
 - management of, 227
- Cyanide chloride, as a chemical weapon, 797-798
- Cyclophosphamide, in small-cell lung cancer, 231
- Cycloserine, for pulmonary disease caused by *Mycobacterium avium* complex, 635
- Cystic echinococcosis, of the lungs, 397-402
- Cystic fibrosis, mycobacteria other than *Mycobacterium tuberculosis* (MOTT) in the setting of, **655-663**
 - antimicrobial treatment, 659-660
 - diagnosis, 657-659
 - epidemiology, 655-656
 - infection after lung transplantation, 661
 - interferon gamma, 660-661
 - recovery of specimens from, 656-657
 - surgical treatment, 660
 - Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Cytokines, innate immune defense by, 288

Cytology, sputum, in diagnosis of roentgenographically occult lung cancer, 59-64. See also *Sputum cytology*.

Cytomegalovirus, in the tropics, as pulmonary manifestation of HIV/AIDS, 362

Cytometry, automated image, high-resolution, in diagnosis of roentgenographically occult lung cancer

D

Decline in lung function, due to coal mine and silica dust, 823-824

Defensins, innate immune defense by, 288

Deisel exhaust, health effects of outdoor air pollution due to, 770

Dendritic cells, innate immune response by, 286

Diagnosis, of mycobacteria other than *Mycobacterium tuberculosis* (MOTT), 585-597, 599-601

acid-fast microscopy, 587

assessing a laboratory's performance, 593

clinical presentation, 599-600

direct nucleic acid amplification assays, 588

DNA chip technology, 591-592

DNA sequencing, 591

genotyping, 592

high-performance liquid chromatography, 590

in cystic fibrosis patients, 657-659

in HIV-infected patients, 668

integration of findings, 600-601

Lady Windemere syndrome, 676-678

making decisions about treatment, 601

mycobacterial culture, 588-589

mycobacteriology, 600

nucleic acid hybridization methods, 589-590

obtaining quality specimens, 586-587

of *M. avium* complex in patients with

pre-existing lung disease, 647-648

of *M. kansasii* disease, 615-616

of pulmonary disease due to rapidly growing mycobacteria, 626-628

polymerase chain reaction and restriction length polymorphism analysis, 590-591

radiographic presentation, 600

species-specific probes on AFB-positive

sputum smears, 588

susceptibility testing, 592

validation of new assays, 592-593

Diet, in lung cancer prevention, 18-21

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, and lung cancer, 67-68

Diffusing capacity

for evaluation of pulmonary impairment and disability, 851-852

in functional evaluation before lung resection, 161

Diloxanide furoate, for amebiasis, 487

Disability, due to pulmonary impairment, determination of, 849-859

definitions, 849

disability evaluation, 857-858

disease-specific assessment, 854-857

asthma, 854-855

chronic obstructive pulmonary disease, 855

obstructive sleep apnea, 857

restrictive lung disease, 856-857

upper airway obstruction, 855-856

evaluation of, clinical approach to, 849-854

arterial blood gas measurement, 854

cardiopulmonary exercise tests, 852-853

chest radiograph, 853-854

computed tomography, 854

history, 850

physical examination, 850-851

pulmonary function tests, 851-852

Disinfectant resistance, in environmental opportunistic mycobacteria, 539-540

Disseminated tuberculosis, survey of HIV seropositivity and, 351-354

DNA chip technology, in diagnosis of nontuberculous mycobacteria, 591-592

DNA fingerprinting, of environmental opportunistic mycobacteria, 532-533

DNA sequencing, in diagnosis of nontuberculous mycobacteria, 591

Drinking water, as habitat for environmental opportunistic mycobacteria, 533-534

Drug susceptibility, in vitro, of *M. kansasii*, 616-617
See also *Susceptibility testing*.

Drug-induced granulomas, in the tropics, 338

Drug-induced pulmonary eosinophilia, 387-388

Dusts, organic, source of exposure for agricultural lung disease, 802

Dysplasia, squamous, and lung cancer, 65-67

E

Early Lung Cancer Action Project (ELCAP) study, 50-55

annual repeat results in, 53

- baseline results in, 52-53
 - diagnostic work of annual repeat positives in, 52
 - diagnostic work of baseline positives in, 52
 - documentation of symptom-prompted diagnoses in, 52
 - enrollment in, 51
 - results summary, 53-55
 - screening test in, baseline and annual repeat in, 51-52
- Echinococcosis, alveolar, of the lungs, 402-405
- cystic, of the lungs, 397-402
 - immunologic aspects of, 301
- Echinococcus granulosus*, 397-402
- Echinococcus multilocularis*, 402-405
- Ecology, physiologic, of environmental opportunistic mycobacteria, 536-540
- Edema, pulmonary, malaria and, 459-460
- ELCAP study. See *Early Lung Cancer Action Project (ELCAP) study*.
- Electrocautery, in lung cancer, 245-246
- Emphysema, due to mineral dust exposure. See also *Coal mine and silica dust, respiratory disease from*, definition of, 763
- epidemiology of, 767
- Entamoeba histolytica*, life cycle, 479-481
- thoracic amebiasis due to, **479-492**
- Environment, as factor in lung cancer, 14-16
- Environmental exposures, lung disease caused by, assessment of exposures, **695-705**
- chemical and biological weapons, pulmonary manifestations of, **783-800**
 - pulmonary impairment and disability, **849-859**
 - tobacco smoke, adult asthma and, **749-761**
- Environmental mycobacteria. See *Mycobacterial disease, nontuberculous*.
- Environmental opportunistic mycobacteria, other than *Mycobacterium tuberculosis*, **529-551**
- habitats of, 533-536
 - aerosols, 534-535
 - animals and birds, 535-536
 - biofilms, 534
 - food, 535
 - instruments, 535
 - miscellaneous samples, 536
 - moldy buildings, 535
 - soil, 534
 - water, 533-534
 - isolation, identification, and characterization of, 530-533
 - DNA fingerprinting, 532-533
 - from soil, 532
 - from water, 531-532
- pathways of infection by, 540
- physiologic ecology of, 536-540
- antibiotic, disinfectant, and heavy-metal resistance, 539-540
 - cell surface hydrophobicity and charge, 536-537
 - conditions of growth, 538-539
 - genomics and genetic variation, 537
 - growth characteristics, 537-538
 - intracellular growth in phagocytic cells, 540
 - metabolism and metabolites, 538
 - structural characteristics, 536
- Environmental tobacco smoke, adult asthma and, **749-761**
- causal association of, 759-760
 - controlled human exposure studies, 759
 - exacerbation of pre-existing adult asthma, 755-759
 - new-onset adult asthma, 749-753
 - new-onset wheezing, 753-755
 - prevalence of exposure to, 749
- Eosinophilic granuloma. See *Langerhans' cell granulomatosis*.
- Eosinophilic lung disease, in the tropics, **377-396**
- pulmonary infiltration with eosinophilia
 - differential diagnosis, 378-379
 - extrinsic (known cause), 380-388
 - allergic bronchopulmonary aspergillosis, 381-383
 - bronchocentric granulomatosis, 383-384
 - chronic brucellosis, 384
 - drug-induced, 387-388
 - fungal infections, 381
 - paragonimiasis, 385-386
 - parasitic infestations, 384-385
 - pleuropulmonary amebiasis, 386
 - pulmonary hydatid cyst, 386
 - tropical pulmonary eosinophilia, 294-295, 387
 - tuberculosis, 380-381
 - immunologic aspects, 299
 - intrinsic (cause unknown), 380, 388-393
 - acute eosinophilic pneumonia, 389-390
 - bronchiolitis obliterans
 - pneumonitis, 390
 - chronic eosinophilic pneumonia, 388-389

- Churg-Strauss syndrome, 390-391
hypereosinophilic syndrome, 392-393
Langerhans' cell granulomatosis, 391-392
Loeffler's syndrome, 388
neoplasm-related, 393
polyarteritis nodosa, 391
sarcoidosis, 393
- Eosinophils, innate immune response by, 286
- Epidemiology, of human pulmonary infection with mycobacteria other than *Mycobacterium tuberculosis*, **553-567**
in Africa, 561-562
in Asia, 562
in Australia, 562-563
in Central and South America, 560
in Europe and the United Kingdom, 560-561
in HIV-infected patients, 665-666
in North America, 554-560
of *M. kansasii* disease, 613-614
of rapidly growing mycobacteria, 624-626
risk factors, 563-564
- Epidoxorubicin, 4-, in small-cell lung cancer, 231
- ERBB family, and lung cancer, 89-91
- Esophageal disease, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- Ethambutol, for pulmonary disease caused by *Mycobacterium avium* complex, 635
in HIV-infected patients, 668-669
in patients with pre-existing lung disease, 648-651
- Ethionamide, for pulmonary disease caused by *Mycobacterium avium* complex, 635
- Etoposide, in small-cell lung cancer, 231
- Exercise testing, cardiopulmonary, in functional evaluation before lung resection, 164-167
- Exposure assessment, occupational and environmental exposures that cause lung disease, **695-705**
- Extrapulmonary tuberculosis, survey of, in area with low prevalence of HIV, **351-354**
- Extrinsic allergic alveolitis, granulomatous lung disease due to, in the tropics, 337
- Extrinsic pulmonary eosinophilia. See *Eosinophilic lung disease*.
- F**
- Familial Mediterranean fever, thoracic and lung involvement in, **505-510**
amyloidosis of, 507-508
chest malignancies and, 506
genetic and pathogenetic background, 505-506
pleuritis and pericarditis in, 506
protection from asthma and, 506-507
recurrent pneumonia and, 506
thromboembolism in, 508
vasculitis of, 508
- Farm workers, agricultural lung disease in, **801-817**
clinical evaluation of, 803
description of workforce, 802
- Federal Black Lung program, 830
- Fever. See *Familial Mediterranean fever*.
- Fingerprinting, DNA, of environmental opportunistic mycobacteria, 532-533
- Flexible bronchoscopy, in lung cancer staging and diagnosis, **137-149**
central lung cancer, 137-140
peripheral lung cancer, 140-145
recent advances in, 147-149
- Flour exposures, studies of work-related asthma and, 742-743
- Fluorescence in situ hybridization, in diagnosis of nontuberculous mycobacteria, 588
- Focal parenchymal lung lesion. See *Solitary pulmonary nodule*.
- Food, as habitat for environmental opportunistic mycobacteria, 535
- Francisella tularensis*, as biological weapon, inhalational tularemia due to, 785-786
- Fumigants, inhalation of, and acute respiratory failure in agriculture workers, 812
- Fungal disease, in the tropics, eosinophilic lung disease in, 381
granulomatous lung diseases due to, 333-334
blastomycosis, 333-334
cryptococcosis, 333
histoplasmosis, 333
paracoccidiomycosis, 334
penicillium infections, 334
respiratory infections as manifestation of HIV/AIDS, 360-362
cryptococcosis, 360-361

histoplasmosis, 361
paracoccidiomycosis, 361
penicilliosis, 361-362

G

Gases, toxic, source of exposure for agricultural lung disease, 802-803

Gender, and immunopathogenesis of Lady

Windemere syndrome, 678

as factor in lung cancer, 4-5, 10, 13

Gene therapy, for lung cancer, 265-277

adeno-associated virus, 266

adenoviruses, 266

approaches to, 267-274

future directions in, 275

immuno-gene therapy, 270-273

inhibition of growth factors, 268-270

interactions with other therapies, 274-275

mutation compensation, 268

nonviral vectors, 266-267

replication-selective viruses and bacteria,
273-274

retroviruses, 266

suicide-gene therapy, 270

with immunotherapy, 273

tumor suppressor gene replacement therapy,
267-268

vectors used in, 265-267

Genes, tumor suppressor, and lung cancer, 85-89

Genetic factors, in chronic beryllium disease,
839-844

in lung cancer, 17-18

Genetic variation, in environmental opportunistic
mycobacteria, 537

Genomics, of environmental opportunistic
mycobacteria, 537

Genotyping, in diagnosis of nontuberculous
mycobacteria, 592

Glycycyclines, for pulmonary disease caused by
rapidly growing mycobacteria, 630

Gnathostomiasis, immunologic aspects, 303

Granuloma, definition of, 329

eosinophilic, 391-392

formation of, 291-293

Granulomatosis, and angitis, allergic. See

Churg-Strauss syndrome.

bronchocentric, eosinophilic disease in, 383-384

in the tropics, bronchocentric, 337

lymphomatoid, 336

primary allergic, 336

Wegener's, 336

Granulomatous lung diseases, in the tropics, 329-339

bacterial diseases, 334-335

brucellosis, 334-335

tularemia, 335

berylliosis, 337-338

causes of, 330

defining granuloma, 329

differential diagnosis, 330-332

drug-induced, 338

fungal diseases, 333-334

blastomycosis, 333-334

cryptococcosis, 333

histoplasmosis, 333

paracoccidiomycosis, 334

penicillium infections, 334

hypersensitivity pneumonitis or extrinsic
allergic alveolitis, 337

morphology, 329-330

mycobacterial diseases, 332-333

leprosy, 333

tuberculosis, 332-333

of unknown causes, 335-337

bronchocentric granulomatosis, 337

lymphoid granulomatosis, 336

primary allergic granulomatosis, 336

sarcoidosis, 335-336

Wegener's granulomatosis, 336

parasitic diseases, 334

leishmaniasis, 334

nematodes, 334

trematodes, 334

versus Whipple's disease, 513-516

Mycobacterium avium complex pulmonary
disease associated with pre-existing, 645

Growth characteristics, of environmental
opportunistic mycobacteria, 537-538

conditions for, 538-539

Growth factors, inhibition of, in lung cancer, 268-270

Gum, nicotene, 30-31

H

HAART. See *Antiretroviral therapy, highly active*.

Habitats, of environmental opportunistic

mycobacteria, 533-536

aerosols, 534-535

animals and birds, 535-536

biofilms, 534

- food, 535
 - instruments, 535
 - miscellaneous samples, 536
 - moldy buildings, 535
 - soil, 534
 - water, 533-534
- Hazard identification, and exposure assessment, 695-705
- Hazardous material events, response to, principles of, 791-792
- Heart, in functional evaluation before lung resection, 163
- Heat stroke, adult respiratory syndrome (ARDS) due to, 451
- Heavy-metal resistance, in environmental opportunistic mycobacteria, 539-540
- Helminthic infections, in epidemiology of tuberculosis in the tropics, 344
- Hemorrhagic mediastinitis, caused by biological weapons, 786-790
- Herpes zoster, in the tropics, as pulmonary manifestation of HIV/AIDS, 362
- High-performance liquid chromatography, in diagnosis of nontuberculous mycobacteria, 590
- High-resolution automated image cytometry, quantitative sputum cytology based on, in diagnosis of roentgenographically occult lung cancer, 62
- Highly active antiretroviral therapy (HAART), interaction with treatment for mycobacteria other than tuberculosis in HIV-infected patients, 665-666, 668-669
- Histoplasmosis, as pulmonary manifestation of HIV/AIDS in tropics, 360-361
- granulomas in, 333
- HIV. See *Human immunodeficiency virus*.
- HIV. See *Human immunodeficiency virus*.
- Home, assessment of exposure to inhalation hazards in, 697-699
 - biological hazards, 699
 - checklist for, 700
 - chemical hazards, 698-699
 - duration of exposure, 699-701
 - exposure levels in, 701-702
 - protection from exposure to, 702-703
- Hot tub use, pulmonary mycobacterial disease in association with, 682-683
- Human immunodeficiency virus (HIV), in the tropics, HIV-associated tuberculosis, diagnosis, 355-356
 - effect of HIV on tuberculosis epidemiology, 343
 - epidemiology, 355
 - extrapulmonary, survey of role of HIV in, 351-354
 - latent, 357
 - radiologic imaging of, 316-317
 - treatment, 356-357, 358

pulmonary manifestations of, 355-367
 - bacterial pneumonias, 357-360
 - fungal respiratory infections, 360-362
 - idiopathic pulmonary processes, 364
 - neoplastic pulmonary diseases, 363-364
 - non-tuberculous mycobacterial diseases, 360
 - parasitic infections, 362
 - tuberculosis, 355-357
 - viral respiratory infections, 362-363

radiologic imaging of pulmonary complications of, 317-319

versus Whipple's disease, 515

interaction of *Mycobacterium avium* and *M. intracellulare* with, 574-575

mycobacteria other than tuberculosis in patients with, 665-674
 - M. avium* complex, 665-670
 - M. genovese*, 671
 - M. gordonae*, 670-671
 - M. kansasii*, 670
 - M. xenopi*, 671
- Humoral hypercalcemia of malignancy, 259
- Hydatid cyst, pulmonary, eosinophilic disease due to, 386
- Hydatid lung disease, in the tropics, 397-408
 - alveolar echinococcosis of lungs, 402-405
 - cystic echinococcosis of lungs, 397-402
 - immunologic aspects, 301
 - radiologic imaging of, 322-324
- Hydrofluoric acid, acute inhalation injury due to, 710
- Hydrogen cyanide, as a chemical weapon, 797-798
- Hygiene hypothesis, 305
- Hypercalcemia of malignancy, humoral, 259
- Hypereosinophilic syndrome, 392-393
- Hyperplasia, adenomatous, atypical, and lung cancer, 67
 - diffuse idiopathic pulmonary neuroendocrine cell, and lung cancer, 67-68

- Hypersensitivity pneumonitis, granulomatous lung disease due to, in the tropics, 337
in agricultural workers, 803-806
clinical presentation, 805
diagnosis, 805
epidemiology, 803-804
etiologic agents, 804
immunopathogenesis, 804-805
treatment, 805-806
vs. organic dust toxic syndrome, 808
- Hyponatremia, of malignancy, management of, 227
- I**
- Ifosfamide, in small-cell lung cancer, 231
- Imaging services, in the tropics, 309-311
- Immune system, components of, 283-293
- Immuno-gene therapy, for lung cancer, 270-273
- Immunocompromised patients, pulmonary *Mycobacterium avium-intracellulare* complex in, 610
- Immunodiagnostic tests, for tropical lung infections, 305
- Immunology, of tropical lung disease, **283-308**
AIDS and tropical infections, 298-299
bacterial toxins and the immune system, 296
components of the immune system, 283-293
helminths and protozoal lung infections, 299-304
immunodeficiency and cancer, 304-305
malnutrition, immune response, and infection, 296
parasites and the immune system, 292, 293-296
protective immunity, 305-306
- Immunotherapy, for mycobacteria other than tuberculosis. See *Interferon-gamma*.
with suicide-gene therapy, for lung cancer, 273
- Impairment, pulmonary. See *Pulmonary impairment*.
- In vitro susceptibility testing.
See *Susceptibility testing*.
- Induced sputum analysis, to test for work-related asthma, 744-745
- Infections, bacterial. See *Bacterial infections*.
non-tuberculous mycobacterial. See *Mycobacterial disease, non-tuberculous*
pulmonary. See *Pulmonary infection*.
viral. See *Viral respiratory infections*.
- Inflammation, airway, noninvasive methods of characterizing, in work-related asthma, 743-745
exhaled nitric oxide, 743-744
induced sputum analysis, 744-745
- Inhalation hazards, associated with industrial unit operations, 697
in work area or home, 698-699
- Inhalation injury, acute, **707-715**
mechanisms of toxicity, 707-708
physical examination, 712-713
prevention, 714
site of injury, 709-710
syndromes caused by specific agents, 710-712
treatment, 713-714
- Inhalational anthrax, bioterrorism-related, 786-790
- Inhalers, nicotene, 32-33
- Inhibition of growth factors, in lung cancer, 268-270
- Instruments, as habitat for environmental opportunistic mycobacteria, 535
- Interferon gamma, for nontuberculous mycobacterial lung disease, caused by *Mycobacterium avium* complex, 637
caused by rapidly growing mycobacteria, 630
in cystic fibrosis patients, 660-661
- Interferons, innate immune defense by, 288
- International System for Staging Lung Cancer, 103-112
- Interstitial inflammatory pneumonitic processes, associated with HIV/AIDS in the tropics, 364
- Intracardiac thrombus, in Behçet's disease, 499
- Intrinsic pulmonary eosinophilia. See *Eosinophilic lung disease*.
- Irritant rhinitis, occupational, 720-721
- Irritants, chronic low-level exposures to, occupational airways diseases from, **727-735**
- Isolation, of environmental opportunistic mycobacteria, 531-532
from soil, 532
from water, 531-532
- Isoniazid, for mycobacterial disease in HIV-infected patients, 670, 671
for pulmonary disease caused by *Mycobacterium avium* complex, 636
for tuberculosis, 346
in HIV patients, 356-357

K

Kalazar. See *Leishmaniasis*.

Kaposi's sarcoma, in the tropics, as pulmonary manifestation of HIV/AIDS, 363
radiologic imaging of, 319-321

Katayama fever, 299

Ketolides, for pulmonary disease caused by rapidly growing mycobacteria, 630

L

Laboratory animal exposures, studies of work-related asthma and, 742-743

Laboratory diagnosis, of mycobacteria other than *Mycobacterium tuberculosis* (MOTT), **585-597**
acid-fast microscopy, 587
assessing a laboratory's performance, 593
direct nucleic acid amplification assays, 588
DNA chip technology, 591-592
DNA sequencing, 591
genotyping, 592
high-performance liquid chromatography, 590
mycobacterial culture, 588-589
nucleic acid hybridization methods, 589-590
obtaining quality specimens, 586-587
of *M. avium* complex in patients with pre-existing lung disease, 647-648
polymerase chain reaction and restriction length polymorphism analysis, 590-591
species-specific probes on AFB-positive sputum smears, 588
susceptibility testing, 592
validation of new assays, 592-593

Lady Windermere syndrome, **675-686**

clinical features, 675-676
diagnosis, 676-678
from colonization to pulmonary manifestations, 678-680
gender and immunopathogenesis of, 678
hot tub use and, 682-683
local and systemic host defenses in, 678
natural history of, 681-682
radiology of, 607-609
therapy, 680-681

Lambert-Eaton myasthenic syndrome, in lung cancer patients, 261-262

Langerhans' cell granulomatosis, eosinophilic disease in, 391-392

Large-cell lung carcinoma, 73-76

Large-cell neuroendocrine carcinoma, 74-75

Laryngeal disorders. See *Upper airway disease, occupational*.

Laser therapy, in lung cancer, 242-245

Latex exposures, studies of work-related asthma and, 742-743

Leishmaniasis, immunologic aspects of, 304
in the tropics, granulomatous lung diseases caused by, 334

Leprosy, granulomas in, 333

Leptospirosis, adult respiratory distress syndrome (ARDS) due to, 451, 474
pulmonary complications of, **469-478**
clinical presentation, 472
diagnosis, 472-473
epidemiology, 470-471
lung involvement, 473-475
pathogenesis, 471-472
prophylaxis, 476
treatment, 475-476

Lewisite, as chemical weapon, irritation and inflammation of lungs and airways due to, 795-797

Linezolid, for pulmonary disease caused by rapidly growing mycobacteria, 630

Loeffler's syndrome, pulmonary eosinophilia in, 388

Lower respiratory tract, acute inhalational injury to, 709-710

Lung (choke) agents, as chemical weapons, irritation and inflammation of lungs and airways due to, 796-797

Lung cancer, adenocarcinoma and, 68-71
adenosquamous carcinoma, 75
age as factor in, 4-5
angiogenesis and, 94
apoptosis and, 94
atypical adenomatous hyperplasia and, 67
atypical carcinoid, 76-78
carcinoma in situ and, 65-67
carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements, 75
carcinomasarcoma, 76
causes of. See also specific causes, e.g., *Cigarette smoking*, **5-18**
central, flexible bronchoscopy in, See *Flexible bronchoscopy, in lung cancer staging and diagnosis*.
cigar smoking and, 5-10
cigarette smoking and, 5-10
relationship between, 27

- classification of. See also *Lung cancer, staging of.* 65, 66, **103-121**
- biologic prognostic factors in, challenge of, 119
- future challenges facing, 116-117
- International System for Staging Lung Cancer in, 103-112
- new technology refinements in, implications of, 118
- PET in, 118-119
- questions related to, 117-118
- regional lymph node classification, 113
- satellite nodules and ipsilateral nodules in non-primary tumor lobes in, 117
- staging systems in, critical evaluation of, 113-116
- diagnosis of, imaging techniques in, **123-136**
- diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and, 67-68
- early detection of, sputum-based approaches to, 39-42
- early, chemoprevention of, direct epithelial delivery of, 43-45
- environmental factors in, 14-16
- epidemiology of, 1-5
- molecular, 83-84
- ERBB family in, 89-91
- gender as factor in, 4-5, 10, 13
- gene therapy for. See also *Gene therapy, for lung cancer.* **265-277**
- genetic factors in, 17-18
- in the tropics, as pulmonary manifestation of HIV/AIDS, 364
- inherited, susceptibility to, 83-84
- large-cell carcinoma, 73-76
- management of, aerosolized drug delivery in, respiratory issues related to, 45-46
- bronchoscopy in. See also *Bronchoscopy, in lung cancer.* **241-256**
- electrocautery in, 245-246
- laser therapy in, 242-245
- lung resection in, functional evaluation before. See also *Lung resection, in lung cancer management.* **159-172**
- preinvasive, **37-48**
- molecular biology of, **83-101**
- molecular changes in, early detection of, 91-94
- prognostic implications in, 94-95
- therapeutic implications of, 84-91
- molecular changes in, diagnostic implications of, 91-94
- mortality related to, reduction in, 37-46
- non-small-cell, stage I, treatment of, **173-190**
- stage II, treatment of, **173-190**
- stage IIIA, treatment of, **191-207**
- stage IIIB, treatment of, **209-224**
- occupational carcinogens as factor in, 15-16
- pathology of, **65-81**
- patients at risk for, 60
- peripheral, flexible bronchoscopy in. See *Flexible bronchoscopy, in lung cancer staging and diagnosis.*
- preinvasive lesions in, 65-71
- prevalence of, 83, 123
- prevention of, **18-21**
- diet in, 18-21
- smoking cessation in. See also *Smoking cessation, in lung cancer prevention.* 21
- proto-oncogenes and, 89
- pulmonary blastoma, 76
- race as factor in, 4-5, 13
- radon and, 14-15
- roentgenographically occult, diagnosis of, sputum cytology in, **59-64**
- screening in, and clinical management integration issues, 43
- CT in, **49-57**
- general issues in, 37-39
- spiral CT in, 42-43
- silica dust exposure and, 829-830
- small-cell, 71-73
- management of, **225-239**
- squamous cell carcinoma and, 68
- squamous dysplasia and, 65-67
- staging of. See also *Lung cancer, classification of.*
- flexible bronchoscopy in, **137-139**
- imaging techniques in, **123-136**
- CT, 128-133
- MRI, 128-133
- PET, 133-134
- International System for, 103-112
- transbronchial needle aspiration in, 145-147
- transthoracic needle biopsy in, **149-153**
- telomerase activation in, 93
- tumor suppressor genes in, 85-89
- typical carcinoid, 76-78
- U.S. trends in, 2-4
- worldwide trends in, 1-2
- Lung diseases. See also *Pulmonary disease.*
- in the tropics. See *Tropical lung disease*
- nonmalignant, pre-existent, 16-17
- Lung diseases. See also *Respiratory diseases.*
- agricultural, **801-817**
- asthma, 807-809
- asthma-like syndrome, 809-810
- bronchitis, 810

- clinical evaluation for, 803
 - hypersensitivity pneumonitis, 803-806
 - organic toxic dust syndrome, 806-807
 - sources of exposure, 802-803
 - mites, 803
 - organic dusts, 802
 - toxic gases, 802-803
 - toxic gas inhalation and acute respiratory failure, 810-812
 - workforce, 802
- chronic beryllium disease, **835-847**
- Lung function, decline in, due to coal mine and silica dust, 823-824
- Lung injury, acute, in malaria, 461-462, 463-465
- Lung resection, in lung cancer management, exercise capacity after, 167
- functional evaluation before, **159-172**
 - age as factor in, 161
 - arterial blood gas measurements, 161
 - cardiac risk, 163
 - cardiopulmonary exercise testing, 164
 - cardiopulmonary reserves, algorithm for, 167-169
 - extent of resection, 163
 - pulmonary function tests in, 161
 - pulmonary hemodynamics, 161-162
 - split function studies, 163-164
 - pulmonary function after, 167
 - tumor resection with lung volume reduction surgery, 169
- Lung transplantation, in cystic fibrosis patients, non-tuberculous mycobacterial lung disease after, 661
- Lymphadenitis, tuberculous, survey of HIV seropositivity and, 351-354
- Lymphoma, non-Hodgkin's, in the tropics, as pulmonary manifestation of HIV/AIDS, 363
- Lymphomatoid granulomatosis, in the tropics, 336
- M**
- Machining fluid exposures, studies of work-related asthma and, 742
- Macrophages, innate immune response by, 286
- Magnetic resonance imaging (MRI), in solitary pulmonary nodule diagnosis, 127
- in solitary pulmonary nodule staging, 128-133
- Malaria, **457-468**
 - adult respiratory distress syndrome (ARDS) due to, 446-449, 461-462, 463-465
 - classification, 457-458
 - immunologic aspects of, 304
 - lung disease in, 458-465
 - acute lung injury and adult respiratory distress syndrome, 461-462
 - clinical management, 465-466
 - drug-induced, 465
 - histopathology, 462-463
 - historical perspective, 458-459
 - pathophysiology, 463-465
 - physiologic and hemodynamic studies, 460-461
 - pregnancy and, 460
 - pulmonary edema and, 459-460
 - radiology, 460
 - respiratory arrest in, 462
 - respiratory signs in, 462- Malignancy(ies). See also *Cancer*, chest, and familial Mediterranean fever, 506
 - humoral hypercalcemia of, 259
 - hyponatremia of, management of, 227
- Malnutrition, immune response, infection and, in tropical lung diseases, 296-297
- Manure pit gases, inhalation of, and acute respiratory failure in agriculture workers, 811-812
- Material safety data sheet, in assessment of hazard exposures, 703-704
- Measles, in the tropics, as pulmonary manifestation of HIV/AIDS, 362-363
- Mediastinitis, hemorrhagic, caused by biological weapons, 786-790
- Medical management. See *Treatment*.
- Mediterranean fever, familial. See *Familial Mediterranean fever*.
- Melioidosis, as pulmonary manifestation of tropical HIV/AIDS, 359-360
 - pulmonary, in the tropics, radiologic imaging of, 326-327
- Meningitis, chronic or recurrent, versus Whipple's disease, 515-516
 - tuberculous, survey of HIV seropositivity and, 351-354
- Mercury, acute inhalation injury due to, 711
- Metabolism, in environmental opportunistic mycobacteria, 538
- Metabolites, in environmental opportunistic mycobacteria, 538

- Metronidazole, for amebiasis, 486-487
- Miliary tuberculosis, survey of HIV seropositivity and, 351-354
- Miners. See *Coal mine and silica dust, respiratory disease from*.
- Mites, source of exposure for agricultural lung disease, 803
- Mixed dust pneumoconiosis. See also *Coal mine and silica dust, respiratory disease from*, definition of, 819
- Moldy buildings, as habitat for environmental opportunistic mycobacteria, 535
- Molecular targeted therapy, in stage IIIB NSCLC, 214-217
in stage IV NSCLC, 214-217
- Monocytes, innate immune response by, 286
- MOTT. See *Mycobacteria other than M. tuberculosis*.
- MRI. See *Magnetic resonance imaging (MRI)*.
- Mucosa-associated lymphoid tissue (MALT), role in disease resistance, 285
- Mucosal surfaces, role in disease resistance, 285
- Multi-drug-resistant tuberculosis, in the tropics, therapy of, 346
- Mustard agents, as chemical weapon, irritation and inflammation of lungs and airways due to, 794-797
- Mutation compensation, for lung cancer, 268
- Mycobacteria other than M. tuberculosis (MOTT)*, **529-686**
diagnosis, differentiating colonization, infection, and disease, **599-601**
clinical presentation, 599-600
integration of findings, 600-601
mycobacteriology, 600
radiographic presentation, 600
treatment decisions, 601
laboratory, **585-597**
acid-fast microscopy, 587
assessing a laboratory's performance, 593
direct nucleic acid amplification assays, 588
DNA chip technology, 591-592
DNA sequencing, 591
genotyping, 592
high-performance liquid chromatography, 590
mycobacterial culture, 588-589
nucleic acid hybridization methods, 589-590
obtaining quality specimens, 586-587
polymerase chain reaction and restriction length polymorphism analysis, 590-591
species-specific probes on AFB-positive sputum smears, 588
susceptibility testing, 592
validation of new assays, 592-593
epidemiology of human pulmonary infection with, **553-567**
in Africa, 561-562
in Asia, 562
in Australia, 562-563
in Central and South America, 560
in Europe and the United Kingdom, 560-561
in North America, 554-560
risk factors, 563-564
in cystic fibrosis patients, **655-663**
antimicrobial treatment, 659-660
diagnosis, 657-659
epidemiology, 655-656
infection after lung transplantation, 661
interferon gamma, 660-661
recovery of specimens from, 656-657
surgical treatment, 660
in HIV-infected patients, **665-674**
M. avium complex, 665-670
M. genovese, 671
M. goodii, 670-671
M. kansasii, 670
M. xenopi, 671
in the environment, **529-551**
habitats of, 533-536
isolation, identification, and characterization of, 530-533
pathways of infection by, 540
physiologic ecology of, 536-540
in women (Lady Windermere syndrome), **675-686**
clinical features, 675-676
diagnosis, 676-678
from colonization to pulmonary manifestations, 678-680
gender and immunopathogenesis of, 678
hot tub use and, 682-683
local and systemic host defenses in, 678
natural history of, 681-682
radiology of, 607-609
therapy, 680-681
Mycobacterium avium-intracellulare complex, in patients with pre-existing lung disease, **643-653**

- medical management of pulmonary disease due to, **633-641**
- radiology of pulmonary disease due to, **603-612**
- Mycobacterium kansasii*, management of disease due to, **613-621**
 - clinical aspects of, 614-615
 - diagnosis of, 615-616
 - in vitro drug susceptibility, 616-617
 - monitoring treatment, 619
 - pathogenesis and epidemiology, 613-614
 - treatment, 617-619
 - pathogenesis of infection, **569-583**
- with *M. avium* and *M. intracellulare*, 569-576
- with *M. fortuitum*, *M. chelonae*, and *M. abscessus*, 577-578
- with *M. kansasii*, 576-577
- radiology of pulmonary *M. avium-intracellulare* complex, **603-612**
 - in the immunocompetent host, 603-610
 - atypical manifestations, 607-610
 - cavitary disease, 606-607
 - classic appearance, 603-604
 - computed tomography, 607
 - focal masses, 609-610
 - Lady Windemere syndrome, 607-609
 - parenchymal disease, 604-606
 - thoracic cage abnormalities, 607
 - in the immunocompromised host, 610
- rapidly growing, pulmonary disease caused by, **623-632**
 - clinical presentation and diagnosis, 626-628
 - epidemiology, 624-626
 - in vitro susceptibility testing, 628
 - microbiology of, 623-624
 - pathophysiology, 624
 - potential future therapies, 630
 - treatment, 628-630
- Mycobacterial disease, granulomatous lung diseases due to, 332-333
 - leprosy, 333
 - tuberculosis, 332-333
- non-tuberculous, other infections, 371
 - disseminated disease, 371
 - lymphadenitis, 371
 - post-inoculation lesions, 371
- non-tuberculous, pulmonary infections, **369-376**
 - as manifestation of HIV/AIDS, 360
 - diagnosis, 373-374
 - epidemiology, 369-371
 - in apparently healthy persons, 372
 - in children, 372-373
 - in immunosuppressed persons, 373
 - in those with predisposing lung disease, 372
 - therapy, 374-375
 - virulence and pathogenicity of environmental mycobacteria, 371
 - versus Whipple's disease, 515
- Mycobacterium abscessus*, and other environmental opportunistic mycobacteria, **529-551**
 - pathogenesis of infection with, 577-578
 - pulmonary disease caused by rapidly growing mycobacteria, **623-632**
- Mycobacterium avium*, and other environmental opportunistic mycobacteria, **529-551**
 - pathogenesis of infection with, 569-576
- Mycobacterium avium* complex (MAC), in the environment, **529-551**
 - pathogenesis of infection with, 569-576
- Mycobacterium avium* complex (MAC) pulmonary disease, in HIV-infected patients, 665-670
 - clinical manifestations, 666-668
 - diagnosis, 668
 - epidemiology, 665-666
 - pathogenesis, 666
 - prophylaxis, 669-670
 - treatment, 668-669
- in patients with pre-existing lung disease, **643-653**
 - clinical presentation, 645-647
 - diagnosis and laboratory evaluation, 647-648
 - treatment, 648-651
 - types of pre-existing diseases associated with, 644-645
- medical management of, **633-641**
 - adjunctive therapy, 637
 - duration of therapy, 637
 - in vitro susceptibility testing, 633-634
 - National Jewish Medical Center policy and procedures for, 638-640
 - preferred agents, regimens, and schedules, 634-637
- radiology of, **603-612**
 - in the immunocompetent host, 603-610
 - atypical manifestations, 607-610
 - cavitary disease, 606-607
 - classic appearance, 603-604
 - computed tomography, 607
 - focal masses, 609-610
 - Lady Windemere syndrome, 607-609
 - parenchymal disease, 604-606
 - thoracic cage abnormalities, 607
 - in the immunocompromised host, 610

- Mycobacterium branderi*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium celatum*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium chelonae*, and other environmental opportunistic mycobacteria, **529-551**
pathogenesis of infection with, 577-578
- Mycobacterium conspicuum*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium fortuitum*, and other environmental opportunistic mycobacteria, **529-551**
pathogenesis of infection with, 577-578
pulmonary disease caused by rapidly growing mycobacteria, **623-632**
- Mycobacterium genavense*, and other environmental opportunistic mycobacteria, **529-551**
in HIV-infected patients, 671
- Mycobacterium goodii*, in HIV-infected patients, 670-671
- Mycobacterium haemophilum*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium heidelbergense*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium interjectum*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium intermedium*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium intracellulare*, and other environmental opportunistic mycobacteria, **529-551**
pathogenesis of infection with, 569-576
- Mycobacterium kansasii*, and other environmental opportunistic mycobacteria, **529-551**
in HIV-infected patients, 670
management of disease due to, **613-621**
clinical aspects of, 614-615
diagnosis of, 615-616
in vitro drug susceptibility, 616-617
monitoring treatment, 619
pathogenesis and epidemiology, 576-577, 613-614
treatment, 617-619
- Mycobacterium lentiflavum*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium magdebergense*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium mageritense*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium marinum*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium scrofulaceum*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium simiae*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium triplex*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium tusciae*, and other environmental opportunistic mycobacteria, 531
- Mycobacterium ulcerans*, and other environmental opportunistic mycobacteria, **529-551**
- Mycobacterium xenopi*, and other environmental opportunistic mycobacteria, **529-551**
in HIV-infected patients, 671
- Mycobacterium avium* complex, as pulmonary manifestation of HIV/AIDS, 360
-
- ## N
- Nasal disorders. See *Upper airway disease, occupational.*
- Nasal spray, nicotine, 32
- National Jewish Medical and Research Center, policy and procedures for inhaled amikacin for pulmonary disease due to *Mycobacterium avium* complex, 638-640
- Natural killer cells, innate immune response by, 286-287
- Nematodes, in the tropics, granulomatous lung diseases caused by, 334
See also *Ascariasis, Strongyloidiasis, Toxocariasis, and Gnathostomiasis.*
- Neoplastic diseases, in the tropics, eosinophilia related to, 393
pulmonary, as manifestation of HIV/AIDS, 363-364
- Nerve agents, as chemical weapons, 791, 793-794
autonomic dysfunction due to, 793-794
classification of, 791
- Neutrophils, innate immune response by, 286
role of in infection by *M. avium* and *M. intracellulare*, 573
- Nicofolan, for paragonimiasis, 427-428
- Nicotene gum, 30-31
- Nicotene inhaler, 32-33

- Nicotene nasal spray, 32
- Nicotene patch, 31-32
- Nicotene replacement therapy, in lung cancer prevention, 30-33
- historical background of, 30
 - nicotene gum, 30-31
 - nicotene inhaler, 32-33
 - nicotene nasal spray, 32
 - nicotene patch, 31-32
 - non-nicotene products, 33
- Nitric oxide, exhaled, to test for work-related asthma, 743-744
- Nitrogen dioxide, inhalation of, and acute respiratory failure in agriculture workers, 311-312
- Nocardiosis, as pulmonary manifestation of tropical HIV/AIDS, 359
- Nodules, pulmonary, solitary. *See also Solitary pulmonary nodules.*, 123-128
- Non-Hodgkin's lymphoma, in the tropics, as pulmonary manifestation of HIV/AIDS, 363
- Non-small-cell lung cancer (NSCLC), occult cancer, treatment of, results of, 175-176
- stage I, prognostic factors in, 180-184
 - treatment of, **173-190**
 - alternatives to surgery, 184-186
 - basic principles of, 174-175
 - definitions related to, 174-175
 - results of, 176-177
 - stage II, prognostic factors in, 180-184
 - treatment of, **173-190**
 - basic principles of, 174-175
 - definitions related to, 174-175
 - results of, 177-180
 - stage IIIA, defined, 191-192
 - diagnosis of, 192-193
 - treatment of, **191-207**
 - adjuvant therapy, 196
 - chemotherapy with radiation therapy, 199-201
 - induction therapy, 196-201
 - radiation therapy, 199
 - surgery alone, 193-195
 - trimodality therapy, 201-204
 - unresectable, chemotherapy and radiation therapy in, 209-212
 - stage IIIB, treatment of, **209-224**
 - chemotherapy in, 213-214
 - molecular targeted therapy in, 214-217
 - radiation therapy in, palliative, 212-213
 - stage IV, treatment of, **209-224**
 - chemotherapy in, 213-214
 - molecular targeted therapy in, 214-217
 - radiation therapy in, palliative, 212-213
- Nontuberculous mycobacteria. *See Mycobacteria other than Mycobacterium tuberculosis.*
- Nonviral vectors, in lung cancer, 266-267
- Nortriptyline, in lung cancer prevention, 33
- NTM (nontuberculous mycobacteria). *See Mycobacteria other than Mycobacterium tuberculosis.*
- Nucleic acid amplification assays, in diagnosis of nontuberculous mycobacteria, 588
- Nucleic acid hybridization methods, in diagnosis of nontuberculous mycobacteria, 589-590
-
- O**
- Obstructive lung disease, assessment of impairment and disability in, 854-856
- Obstructive sleep apnea, assessment of pulmonary impairment and disability, 857
- Occupational carcinogens, as factor in lung cancer, 15-16
- Occupational lung diseases, acute inhalation injury, **707-715**
- agricultural, **801-817**
 - airways diseases from chronic low-level exposures to irritants, **727-735**
 - assessing exposures causing, **695-705**
 - chronic beryllium disease, **835-847**
 - coal mine and silica dust, **819-834**
 - environmental tobacco smoke and adult asthma, **749-761**
 - pulmonary impairment due to, evaluation of disability, **849-859**
 - work-related asthma, **737-747**
- Occupational upper airway disease, **717-725**
- Opportunistic mycobacteria, other than *Mycobacterium tuberculosis*, in the environment, **529-551**
- Optoclonus-myoelonus, 260-261
- Organic dust toxic syndrome, in agriculture workers, 806-807
- clinical presentation, 807
 - epidemiology, 806
 - etiologic agents, 806
 - pathogenesis, 806-807
 - treatment, 807
 - vs. hypersensitivity pneumonitis, 808

Organic dusts, source of exposure for agricultural lung disease, 802

Organophosphate poisoning, adult respiratory syndrome (ARDS) due to, 451

Outdoor air pollution. See *Air pollution, outdoor*.

Oxazolidinones, for pulmonary disease caused by rapidly growing mycobacteria, 630

Ozone, acute inhalation injury due to, 711-712
health effects of air pollution due to, 767-768, 770-771

P

Paracoccidiomycosis, as pulmonary manifestation of HIV/AIDS in tropics, 360-361

Paragonimiasis, **409-419, 421-431**
pulmonary, in the tropics, anatomopathologic characteristics, 423-424
clinical manifestations, 411-414, 422-423
diagnosis, 414-416, 423, 425-427
eosinophilic disease in, 385-386
epidemiology, 410-411, 428
geographic distribution, 421
historical background, 421
immunologic aspects, 300-301
prognosis, 428
radiologic findings, 424-425
radiologic imaging of, 325-326

Paragonimus species, life cycle of, 409-410, 422
taxonomy, 421
treatment, 416-417, 427-428

Paraneoplastic syndromes, and bronchogenic carcinoma, **257-264**
management of, 227-228
neurologic, 259-262

Paraquat poisoning, adult respiratory syndrome (ARDS) due to, 451

Parasites, antibody responses to, 291
causing respiratory illness in the tropics, 292, 293-296
evasion of host defense mechanisms by, 295-296
See also specific parasites.

Parasitic diseases, in the tropics, as pulmonary manifestation of HIV/AIDS, 362
eosinophilia in, 384-385
granulomatous lung diseases caused by, 334
immune mechanisms in pulmonary, 293-296
See also specific parasites.

Parenchymal changes, pulmonary, in Behçet's disease, 498

Parenchymal disease, pulmonary, due to *Mycobacterium avium-intracellulare* complex, radiology of, 604-606

Particulate matter, health effects of outdoor air pollution due to, 763, 764-767, 768-770
acute effects of, 764-766
cardiovascular disease and, 769-770
chronic effects of, 766-767
concentrated airborne particles, 769
effects of, by particle size, 767

Pathogenesis, of infection caused by mycobacteria other than *M. tuberculosis*, **569-583**
in HIV-infected patients, 666
M. avium and *M. intracellulare*, 569-576
M. fortuitum, *M. chelonae*, and *M. abscessus*, 577-578, 624
M. kansasii, 576-577, 613-614

Penicilliosis, as pulmonary manifestation of HIV/AIDS in tropics, 360-361

Pericarditis, in familial Mediterranean fever, 506

PET. See *Positron emission tomography (PET)*.

pH, for growth of environmental opportunistic mycobacteria, 538

Phagocytic cells, human, growth of environmental opportunistic mycobacteria in, 540
infection of, by *M. avium* and *M. intracellulare*, 572-573
innate immune response by, 285-286
microorganisms' evasion of killing by, 287-288

Phosgene, acute inhalation injury due to, 712
as a chemical weapon, irritation and inflammation of lungs and airways due to, 796-797

Phosgene oxime, as chemical weapon, irritation and inflammation of lungs and airways due to, 795-797

Photodynamic therapy, in lung cancer, 250-253

Physician's report, on pulmonary impairment and disability, 857-858

Physiologic ecology, of environmental opportunistic mycobacteria, 536-540
antibiotic, disinfectant, and heavy-metal resistance, 539-540
cell surface hydrophobicity and charge, 536-537
conditions of growth, 538-539

- genomics and genetic variation, 537
 - growth characteristics, 537-538
 - intracellular growth in phagocytic cells, 540
 - metabolism and metabolites, 538
 - structural characteristics, 536
- Plague, pneumonic, bioterrorism-related, 784-785
- Plasmodium falciparum*, adult respiratory distress syndrome (ARDS) due to malaria caused by, 446-449
- malaria and the lung, 451-468
- Plasmodium vivax*, adult respiratory distress syndrome (ARDS) due to malaria caused by, 448
- Pleurisy, tuberculous, survey of HIV seropositivity and, 351-354
- Pleuritic disease, in Behçet's disease, 498
- Pleuritis, in familial Mediterranean fever, 506
- Pneumococcal pneumonia, as pulmonary manifestation of tropical HIV/AIDS, 357-359
- Pneumoconiosis. See also *Coal mine and silica dust, respiratory disease from*, definition of, 819
- "mixed dust," 819
 - legal, 820
- Pneumocystis carinii* pneumonia, as pulmonary manifestation of tropical HIV/AIDS, 298-299, 359
- Pneumonia(s), in the tropics, acute eosinophilic, 389-390
- bacterial, as pulmonary manifestation of HIV/AIDS, 357-360
 - meliodosis, 359-360
 - nocardiosis, 359
 - pneumococcal, 357-359
 - Pneumocystis carinii*, 359
 - Rhodococcus equi* infection, 360
 - chronic eosinophilic, 388-389
 - recurrent, in familial Mediterranean fever, 506
- Pneumonic plague, bioterrorism-related, 784
- Pneumonitis, hypersensitivity. See *Hypersensitivity pneumonitis*.
- Pneumonitis, acute, caused by biological weapons, 784-786
- Pollution. See *Air pollution, outdoor*.
- Polyarteritis nodosa, eosinophilic disease in, 391
- Polymerase chain reaction, in diagnosis of nontuberculous mycobacteria, 590
- Positron emission tomography (PET), in lung cancer staging, 118-119
- in solitary pulmonary nodule diagnosis, 137-128
 - in solitary pulmonary nodule staging, 133-134
- Praziquantel, for paragonimiasis, 427
- Pre-existing lung disease, *Mycobacterium avium* complex in patients with, 643-653
- Pregnancy, malaria and pulmonary edema in, 460
- Progressive massive fibrosis. See also *Coal mine and silica dust, respiratory disease from*, definition of, 819
- Prophylaxis, for *Mycobacterium avium* complex in HIV-infected patients, 669-670
- Proto-oncogenes, and lung cancer, 89
- Protozoal lung infections, immunologic aspects, 303-304
- See also *Amebiasis, Toxoplasmosis, Malaria, Leishmaniasis, and Chagas' disease*.
- Pulmonary artery aneurysm, in Behçet's disease, 494-498
- Pulmonary blastoma, 76
- Pulmonary disease, due to mycobacteria other than *Mycobacterium tuberculosis*, due to rapidly growing mycobacteria, 623-632
- epidemiology of, 553-567
 - with *M. avium-intracellulare* complex, medical management of, 633-641
 - radiology of, 603-612
- Pulmonary edema, malaria and, 459-460
- Pulmonary function tests, 851-852
- diffusing capacity, 851-852
 - in functional evaluation before lung resection, 161
 - spirometry, 851-852
- Pulmonary hemodynamics, in functional evaluation before lung resection, 161-162
- Pulmonary impairment, and determination of disability, 849-859
- definitions, 849
 - disability evaluation, 857-858
 - disease-specific assessment, 854-857
 - asthma, 854-855
 - chronic obstructive pulmonary disease, 855
 - obstructive sleep apnea, 857
 - restrictive lung disease, 856-857
 - upper airway obstruction, 855-856

- evaluation of, clinical approach to, 849-854
 - arterial blood gas measurement, 854
 - cardiopulmonary exercise tests, 852-853
 - chest radiograph, 853-854
 - computed tomography, 854
 - history, 850
 - physical examination, 850-851
 - pulmonary function tests, 851-852

Pulmonary infections, non-tuberculous. See *Mycobacterial disease, non-tuberculous*.

Pulmonary infiltration with eosinophilia (PIE) syndrome. See *Eosinophilic lung disease*.

Pulmonary neuroendocrine cell hyperplasia, diffuse idiopathic, and lung cancer, 67-68

Pulmonary nodule, solitary. See also *Solitary pulmonary nodule*, 123-128

Pulmonary tuberculosis. See *Tuberculosis*.

Q

Quinine, for malaria, 465-466

R

Race, as factor in lung cancer, 4-5, 13

Radiation fibrosis, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645

Radiation therapy, in non-small-cell lung cancer, 199

- in small-cell lung cancer, 232-233
- in stage III NSCLC, 212-213
- in stage IIIA unresectable NSCLC, 209-211
- in stage IIIB NSCLC, 209-211
- in stage IV NSCLC, 212-213
- with chemotherapy, in non-small-cell lung cancer, 199-201

Radiographs, chest, for evaluation of pulmonary impairment and disability, 853-854

- for respiratory disease from coal mine and silica dust, 822-823, 826-828

Radiology, lung, in the tropics, 309-328

- amebiasis, 321-322, 484-485
- HIV, and pulmonary tuberculosis, 316-317
 - pulmonary complications, 317-319
- hydatid disease, 322-324
- imaging services in, 309-311
- in wider context of health care, 311-314
- Kaposi's sarcoma, 319-321
- malaria, 460
- meliodosis, 326-327

paragonimiasis, 325-326

pulmonary tuberculosis, 314-316

- and HIV, 316-317

strongyloidiasis, pulmonary, 325

of pulmonary *Mycobacterium avium*-intracellular complex, 603-612

in the immunocompetent host, 603-610

atypical manifestations, 607-610

cavitary disease, 606-607

classic appearance, 603-604

computed tomography, 607

focal masses, 609-610

in patients with pre-existing lung disease, 647

Lady Windemere syndrome, 607-609

parenchymal disease, 604-606

thoracic cage abnormalities, 607

in the immunocompromised host, 610

presentation of nontuberculous mycobacteria on, 600

Radon, as factor in lung cancer, 14-15

Rapidly growing mycobacteria, pathogenesis of infection with, 577-578

pulmonary disease caused by, 623-632

clinical presentation and diagnosis, 626-628

epidemiology, 624-626

in vitro susceptibility testing, 628

microbiology of, 623-624

pathophysiology, 624

potential future therapies, 630

treatment, 628-630

Respiratory arrest, in malaria, 462

Respiratory disease, due to occupational and environmental exposures, 695-859

acute inhalation injury, 707-715

agricultural lung disease, 801-817

assessment of exposures, 695-705

chemical and biological agents, intentionally released, 783-800

chronic beryllium disease, genetic and exposure risks, 835-847

chronic low-level exposure to irritants, airways diseases due to, 727-735

from coal mine and silica dust, 819-834

outdoor air pollution, 763-782

pulmonary impairment and disability, 849-859

tobacco smoke, environmental, and adult asthma, 749-761

upper airways disease, occupational, 717-725

work-related asthma, 737-747

Respiratory disorders, aerosolized drug delivery in lung cancer management and, 45-46

- Respiratory tract, acute inhalational injury to, **707-715**
 defense mechanisms of, 283
- Restriction fragment length polymorphism analysis, in diagnosis of nontuberculous mycobacteria, 590-591
- Restrictive lung disease, assessment of pulmonary impairment and disability, 855-856
- Retinopathy(ies), cancer-associated, 261
- Retrovirus(es), in lung cancer, 266
- Rhinitis, occupational, allergic, 719-720
 irritant, 720-721
- Rhodococcus equi* infection, as pulmonary manifestation of tropical HIV/AIDS, 360
- Rifabutin, for HIV-related tuberculosis, 357, 358
 in HIV patients, 356-357
 for pulmonary disease caused by *Mycobacterium avium* complex, for Lady Windemere syndrome, 680
 in HIV-infected patients, interactions with antiretroviral drugs, 669
 in patients with pre-existing lung disease, 648
- Rifampin, for pulmonary disease caused by *Mycobacterium avium* complex, 634-635
 in patients with pre-existing lung disease, 648-651
 for tuberculosis, 346
 in HIV patients, 356-357
- Rifamycin, for pulmonary disease caused by *Mycobacterium avium* complex, in patients with pre-existing lung disease, 648
- Risk factors, for human pulmonary infection with mycobacteria other than *Mycobacterium tuberculosis*, 563-564

S

- Salinity, for growth of environmental opportunistic mycobacteria, 539
- Sarcoidosis, in the tropics, eosinophilic disease in, 393
 granulomatous lung diseases caused by, 335-336
 versus Whipple's disease, 515
- Sarin. See *Nerve agents, as chemical weapons*.
- Schistosoma, eosinophilic lung diseases caused by, 384-385
 granulomatous lung diseases caused by, 334
 life cycle, 433-434
- Schistosomiasis, pulmonary, **433-443**
 chronic, 440-441
 clinical manifestations, 434-435
 early (acute), 435-440
 immunologic aspects, 299-300
 prevention, 441-442
- Scorpion bite, adult respiratory syndrome (ARDS) due to, 451
- SIADH. See *Syndrome of inappropriate antidiuretic hormone*.
- Silica dust, respiratory disease due to exposure to, **819-834**
 chronic obstructive lung disease caused by, 824
 clinical evaluation for, 824-828
 exposed populations, 821
 prevalence rates of, 822-823
 special syndromes of, 828-830
 accelerated silicosis, 829
 acute, or silicoproteinosis, 829
 lung cancer and, 829-830
 simple and complicated silicosis, 828
 treatment of, 830-831
 compensation, 830
 components of medical legal opinions, 831
 removal from exposure, 830
 supportive care, 830
- Silicoproteinosis, 829
- Silicosis, in epidemiology of tuberculosis in the tropics, 343-344
Mycobacterium avium complex pulmonary disease associated with pre-existing, 645
- Silicosis. See also *Silica dust, respiratory disease due to exposure to*, definition of, 819
- Sinusitis, due to occupational exposure, 721
- Skin, role in disease resistance, 284-285
- Sleep apnea, obstructive, assessment of pulmonary impairment and disability, 857
- Small-cell lung cancer, 71-73
 clinical features of, 72
 combined, 72
 diagnosis of, 225-227
 differential diagnosis of, 73
 management of, **225-239**
 chemotherapy in. See also *Chemotherapy, in small-cell lung cancer*, 229-232
 combination therapy, long-term survivors of, 234-235
 Cushing's syndrome, 227

- hyponatremia of malignancy, 227
 - paraneoplastic syndromes, 227-228
 - neurologic, 227-228
 - radiation therapy in, 232-233
 - surgical, 233-234
 - prognosis of, 72
 - prognostic factors in, 229
 - staging of patients with, 228-229
- Smoke inhalation, acute inhalation injury due to, 710
- Smoke, tobacco, environmental, and adult asthma, **749-761**
- causal association of, 759-760
 - exacerbation of pre-existing adult asthma, 755-759
 - new-onset adult asthma and, 749-752
 - new-onset wheezing and, 753-754
 - prevalence of exposure to environmental, 749
- Smoker(s), nicotine levels in, 30
- Smoking, cigar, lung cancer caused by, 10
- cigarette, lung cancer caused by, 5-10
- Smoking cessation, in lung cancer prevention, **21, 27-36**
- bupropion in, 33
 - clonidine in, 33
 - combination pharmacotherapy in, 34
 - nicotine replacement therapy in. See also *Nicotine replacement therapy*, 30-33
 - nortriptyline in, 33
 - services provided in the medical setting, 34
 - U.S. Public Health Service guidelines for, 29-30
 - unproved pharmacotherapies in, 34
- Smoking-related chronic obstructive pulmonary disease, *Mycobacterium avium* complex pulmonary disease associated with pre-existing, 644-645, 647
- Soil, as habitat for environmental opportunistic mycobacteria, 534
- isolation of mycobacteria other than *Mycobacterium tuberculosis* from, 532
- Solitary pulmonary nodule, defined, 123
- diagnosis of, imaging techniques in, 123-128
 - CT, 124-127
 - MRI, 127
 - PET, 127-128
- Spirometry
- for evaluation of pulmonary impairment and disability, 851-852
 - in functional evaluation before lung resection, 161
- Split function studies, in functional evaluation before lung resection, 163-164
- Sputum, assessment of, in early detection of lung cancer, 39-42
- Sputum cytology, in diagnosis of roentgenographically occult lung cancer, **59-64**
- abnormal protein overexpression in, 61-62
 - molecular marker identification in, 61
 - quantitative, 62
 - sputum collection and handling in, 60-611
- Squamous cell carcinoma, and lung cancer, 68
- Squamous dysplasia, and lung cancer, 65-67
- Streptomycin, for tuberculosis, 346
- Strongyloidiasis
- in the tropics, eosinophilic lung diseases in, 384
 - immunologic aspects, 301-302
 - pulmonary, as manifestation of HIV/AIDS, 325
 - radiologic imaging of, 325
- Strongyloidosis, adult respiratory distress syndrome (ARDS) due to, 450
- Suicide-gene therapy, for lung cancer, 270
- with immunotherapy, 273
- Sulfur dioxide, acute inhalation injury due to, 711
- Superior vena cava, occlusion of, in Behçet's disease, 498-499
- Surfactant, pulmonary, innate immune defense by, 288
- Surgical resection, for nontuberculous mycobacterial pulmonary disease, caused by *Mycobacterium avium* complex, 637
- in patients with pre-existing lung disease, 650
 - caused by rapidly growing mycobacteria, 629
 - in cystic fibrosis patients, 660
- Susceptibility testing, in vitro, in diagnosis of nontuberculous mycobacterial pulmonary disease, 592
- with *Mycobacterium avium* complex, 633-634
 - with rapidly growing mycobacteria, 628
- Syndrome of inappropriate antidiuretic hormone (SIADH), 258-259
-
- T**
- T lymphocytes, role in immune system, 289-290

- Telithromycin, for pulmonary disease caused by rapidly growing mycobacteria, 630
- Telomerase activation, in lung cancer, 93
- Temperature, for growth of environmental opportunistic mycobacteria, 538-539
- Terrorism. See *Biological weapons and Chemical weapons*.
- Thioacetazone, for tuberculosis, 346, 356
- Thoracic cage abnormalities, due to *Mycobacterium avium-intracellulare* complex, radiology of, 607
- Thromboembolism, in familial Mediterranean fever, 508
- Thrombus, intracardiac, in Behçet's disease, 499
- Tobacco smoke, environmental, adult asthma and, **749-761**
causal association of, 759-760
exacerbation of pre-existing adult asthma, 755-759
new-onset adult asthma and, 749-752
new-onset wheezing and, 753-754
prevalence of exposure to, 749
- Toxic gases, inhalation of, and acute respiratory failure, 810-812
anhydrous ammonia, 812
fumigants, 812
manure pit gases, 811-812
nitrogen dioxide, 810-811
source of exposure for agricultural lung disease, 802-803
- Toxicariasis, immunologic aspects, 303
- Toxoplasmosis, immunologic aspects of, 304
- Tracheobronchial tumor, bronchoscopic palliation of, 241-242
- Transbronchial needle aspiration, in lung cancer staging and diagnosis, 145-147
- Transplantation, lung, in cystic fibrosis patients, nontuberculous mycobacterial lung disease after, 661
- Transthoracic needle biopsy, in lung cancer staging and diagnosis, **149-153**
complications of, 152-153
contraindications to, 150
diagnostic yield from, 151-152
indications for, 150
perspective on, 153
technique of, 150-151
- Treatment, of pulmonary disease due to nontuberculous mycobacteria, for Lady Windemere syndrome, 680-681
for *Mycobacterium avium* complex, **633-641**
in HIV-infected patients, 668-669
in patients with pre-existing lung disease, 648-651
for rapidly growing mycobacteria, 628-630
in cystic fibrosis patients, 659-660
- Trematodes, in the tropics, granulomatous lung diseases caused by, 334
- Triclabendazole, for paragonimiasis, 416-417, 428
- Trimodality therapy, for non-small-cell lung cancer, 201-204
- Triple-drug therapy. See *Clarithromycin, Rifampin, and Ethambutol*.
- Tropical eosinophilia, pulmonary, 294-295, 387
- Tropical lung disease, 283-517
amebiasis, thoracic, **479-492**
Behçet's disease, pulmonary complications, **493-503**
eosinophilic, **377-397**
extrapulmonary tuberculosis, and relationship to HIV, **351-354**
familial Mediterranean fever, thoracic and lung involvement, **505-510**
granulomatous, **329-339**
hydatid (echinococcosis/hydatidosis), **397-408**
immunologic aspects, **283-308**
leptospirosis, pulmonary complications, **469-478**
malaria and the lung, **457-468**
mycobacterial pulmonary infections, nontuberculous, **369-376**
paragonimiasis, **409-419, 421-431**
radiologic findings, **309-328**
schistosomiasis, pulmonary, **433-443**
tuberculosis, **341-350**
Whipple's disease, **511-517**
- Tropics, lung diseases in. See *Tropical lung disease*
- Tuberculin skin testing, limitations of, in adults, 345
- Tuberculosis, in the tropics, **341-350**
as cause of adult respiratory distress syndrome (ARDS), 449-450
as pulmonary manifestation of HIV/AIDS, 355-357

- diagnosis, 355-356
- epidemiology, 355
- latent, 357
- treatment, 356-357
- diagnosis, in resource-poor settings, 345-346
- eosinophilic lung disease in, 380-381
- epidemiology, 341-345
- extrapulmonary, survey of, in area with low prevalence of HIV, **351-354**
- prevention strategies, 346-347
- radiologic imaging of pulmonary, 314-316
- sequelae, 347
- therapy, 346
- Mycobacterium avium* complex pulmonary disease associated with pre-existing, 645
- radiologic imaging of pulmonary, and HIV, 316-317
- therapy, directly observed, 346
- in multi-drug-resistance, 346
- Tuberculous epidemics, current global, 342-343
- effect of HIV on, 343
- general patterns, 341
- Tularemia, in the tropics, granulomatous lung diseases caused by, 335
- Tularemia, inhalational, bioterrorism-related, 785-786
- Tumor suppressor gene replacement therapy, for lung cancer, 267-268
- Tumor suppressor genes, and lung cancer, 85-89
- Tumor(s), tracheobronchial, bronchoscopic palliation of, 241-242
- Typhoid, adult respiratory distress syndrome (ARDS) due to, 450

U

- Ultrasonography. See *Imaging services and Radiology*.
- Upper airway, structure and function, 717-718
- Upper airway disease, obstruction, assessment of pulmonary impairment and disability, 855-856
- occupational, **717-725**
 - allergic rhinitis, 719-720
 - irritant rhinitis, 720-721
 - irritant-induced vocal cord dysfunction, 721-724
 - sinusitis, 721
- Upper airway injury, acute inhalational, 709

V

- Vaccination, and protective immunity against tropical lung infections, 305-306
 - Bacillus Calmette-Guerin* (BCG), for prevention of tuberculosis, 346-347
- Vasculitis, of familial Mediterranean fever, pulmonary involvement in, 508
- Venous occlusions, in Behçet's disease, 498-499
- Vesicants. See *Blister agents*.
- Viral respiratory infections, in the tropics, as pulmonary manifestation of HIV/AIDS, 362-363
 - cytomegalovirus, 362
 - herpes zoster, 362
 - measles, 362-363
 - primary HIV infection of lung, 362
 - secondary pulmonary viral infection, 362
- Vocal cord dysfunction, occupational irritant-induced, 721-724

W

- Water, as habitat for environmental opportunistic mycobacteria, 533-534
 - isolation of mycobacteria other than *Mycobacterium tuberculosis* from, 531-532
- Wegener's granulomatosis, in the tropics, 336
- Weil's syndrome. See *Leptospirosis*.
- Wheezing, new-onset of, and environmental tobacco smoke, 753-755
- Whipple's disease, **511-517**
 - clinical features, 511-512
 - diagnosis, 513
 - differential diagnosis, vs. granulomatous disorders, 513-516
 - immunopathology, 512-513
 - treatment and outcome, 516
- Women, mycobacteria other than *M. tuberculosis* (MOTT) in (Lady Windemere syndrome), **675-686**
 - clinical features, 675-676
 - diagnosis, 676-678
 - from colonization to pulmonary manifestations, 678-680
 - gender and immunopathogenesis of, 678
 - hot tub use and, 682-683
 - local and systemic host defenses in, 678
 - natural history of, 681-682
 - radiology of, 607-609
 - therapy, 680-681

Work-related asthma, 737-747

definition, 737, 739

diagnosis, 737-739

incidence and prevalence, 739-741

longitudinal inception cohort and apprentice studies, 742-743

aluminum industry exposures, 742

laboratory animal, flour, and latex exposures, 742-743

machining fluid exposures, 742

noninvasive methods of characterizing airway inflammation, 743-745

exhaled nitric oxide, 743-744

induced sputum analysis, 744-745

Workman's compensation, for disability due to occupational disease, evaluation of pulmonary impairment and disability, 857-858

for coal mine and silica dust-induced lung disease, 830

Workplace, assessment of exposure to inhalation

hazards in, 697-699

biological hazards, 699

chemical hazards, 698-699

duration of exposure, 699-701

exposure levels in, 701-702

protection from exposure to, 702-703

reading a material safety data sheet, 703-704

XX-rays, chest. *See Radiographs, chest.*

Y*Yersinia pestis*, as biological weapon, pneumonic plague due to, 784-785

Z

Zoonoses, paragonimiasis, 409-431, 421-431